Paragon 28, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2021
March 08, 2022 at 09:01 pm
Share
Paragon 28, Inc. provided revenue guidance for the first quarter and full year of 2021. For the first quarter of 2022, the company expects net revenue growth to be in a range of 13% to 16%, compared to the first quarter of 2021.
The company expects 2022 net revenue to be in a range of $167.0 million to $171.0 million, representing annual growth of approximately 13% to 16%.
Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Companyâs suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patientâs anatomical and surgical requirements.
PARAGON 28, INC. 
